Scholars Central

ArticlePublished 22 Jul 2016

A clinical update on the use of Resolute stents with dual anti-platelet therapy interruption

Authors: C OMahony, M Rothman & A Mathur

Interventional Cardiology

Volume 6 · Issue 5 · Pages 453–462

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Percutaneous coronary intervention is currently the most commonly used revascularization procedure. This success is a direct consequence of the improved medium- and long-term target vessel patency achieved with drug-eluting stents (DES). However, DES are associated with stent thrombosis (ST), a rare but potentially catastrophic complication. Early interruption of dual anti-platelet therapy (DAPT) is a major risk factor for ST and guidelines recommend a minimum duration of DAPT of 6 to 12 months post implantation. Recently published observational data suggest that premature DAPT interruption is not associated with ST in patients treated with the second-generation Resolute zotarolimus-eluting stent. This article reviews the background to the development of Resolute DES and reviews recently published data on ST and DAPT interruption.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Interventional Cardiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInterventional Cardiology
  • SubjectCardiology
  • BylineArticles whose byline prints “C OMahony”
  • BylineArticles whose byline prints “M Rothman & A Mathur”